*** Welcome to piglix ***

Epoetin alfa

Epoetin alfa
Clinical data
AHFS/Drugs.com Monograph
MedlinePlus a692034
Pregnancy
category
  • Unknown
Routes of
administration
IV or subcutaneous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
ChEMBL
Chemical and physical data
Formula C815H1317N233O241S5
Molar mass 18396.1 g/mol
 NYesY (what is this?)  

Epoetin alfa (rINN) /ɛˈp.tn/ is a human erythropoietin produced in cell culture using recombinant DNA technology. Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.

Epoetin is manufactured and marketed by Amgen under the trade name Epogen. Johnson & Johnson subsidiary Janssen Biotech (formerly Ortho Biotech Products, LP), sells the same drug under the name Procrit, pursuant to a product license agreement. The average cost per patient in the U.S. was $8,447 in 2009. Darbepoetin alfa (rINN) /dɑːrbəˈpɔɪtn/ is a glycosylation analog of erythropoietin containing two additional N-linked carbohydrate chains, also manufactured and marketed by Amgen, with a trade name of Aranesp. The FDA warnings and safety precautions for Procrit, Epogen and Aranesp are identical.


...
Wikipedia

...